Abstract
Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.
| Original language | English |
|---|---|
| Journal | Cancer Letters |
| DOIs | |
| Publication status | Accepted/In press - 2015 |
Fingerprint
Keywords
- Cancer
- Endothelial cells
- Novel antiangiogenic therapies
- Proangiogenic factors
- Tumor angiogenesis
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. / Marech, Ilaria; Leporini, Christian; Ammendola, Michele; Porcelli, Mariangela; Gadaleta, Cosmo Damiano; Russo, Emilio; De Sarro, Giovambattista; Ranieri, Girolamo.
In: Cancer Letters, 2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment
AU - Marech, Ilaria
AU - Leporini, Christian
AU - Ammendola, Michele
AU - Porcelli, Mariangela
AU - Gadaleta, Cosmo Damiano
AU - Russo, Emilio
AU - De Sarro, Giovambattista
AU - Ranieri, Girolamo
PY - 2015
Y1 - 2015
N2 - Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.
AB - Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.
KW - Cancer
KW - Endothelial cells
KW - Novel antiangiogenic therapies
KW - Proangiogenic factors
KW - Tumor angiogenesis
UR - http://www.scopus.com/inward/record.url?scp=84939864830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939864830&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2015.07.028
DO - 10.1016/j.canlet.2015.07.028
M3 - Article
AN - SCOPUS:84939864830
JO - Cancer Letters
JF - Cancer Letters
SN - 0304-3835
ER -